We showed that FGFR inhibition led to a pronounced reduction in glucose uptake into FGFR2-driven ICC cells in vitro and loss of FDG-PET signal in xenograft tumors. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.